| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| VASO Aktie jetzt für 0€ handeln | |||||
| Mo | Vasomedical reports Q3 results | 1 | Seeking Alpha | ||
| Mo | Vaso Corporation Announces Financial Results for Third Quarter of 2026 | 1 | GlobeNewswire (USA) | ||
| 14.08. | Vaso Corporation Announces Financial Results for Second Quarter of 2026 | 458 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a business portfolio in professional sales services and proprietary non-invasive... ► Artikel lesen | |
| 03.08. | Vaso Corporation Completes Sale of NetWolves Network Services to COEO Solutions | 325 | GlobeNewswire (Europe) | Vaso Corporation137 Commercial StreetPlainview, New York 11803Tel: (516) 997-4600 Fax: (516) 997-2299 Investor Contact:Jonathan NewtonInvestor RelationsPhone: 516-997-4600Email: jnewton@vasocorporation.com... ► Artikel lesen | |
| 31.07. | VASO Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 23.07. | Vaso Corporation beruft Shaun McMeans in den Verwaltungsrat | 1 | Investing.com Deutsch | ||
| 23.07. | Vaso appoints Shaun McMeans to board of directors | 1 | Investing.com | ||
| 23.07. | Vaso Corporation Appoints Shaun McMeans to Board of Directors | 243 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., July 23, 2026 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and IT services, professional... ► Artikel lesen | |
| 23.07. | VASO Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 30.06. | VASO Global Raises Over £5M in Venture, Grant, and Debt Funding Round | 1 | FinSMEs | ||
| 30.06. | VASO Global wins support for recycled glass panels | 1 | The Construction Index | ||
| 15.05. | Vaso Corporation Announces Financial Results for First Quarter of 2026 | 476 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., May 15, 2026 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and IT services, professional... ► Artikel lesen | |
| 31.03. | Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year 2025 | 275 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., March 31, 2026 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and IT services, professional... ► Artikel lesen | |
| 17.12.25 | Vaso Corporation Announces Fifth Extension of Sales Representation Agreement with GE HealthCare | 500 | GlobeNewswire (Europe) | Vaso Corporation137 Commercial StreetPlainview, New York 11803Tel: (516) 997-4600 Fax: (516) 997-2299 Investor Contact:Jonathan NewtonInvestor RelationsPhone: 516-997-4600 Email: jnewton@vasocorporation.com... ► Artikel lesen | |
| 19.11.25 | NANO-X IMAGING LTD: Nanox Reaches Agreement with Vaso Corporation to Acquire VasoHealthcare IT, Accelerating U.S. Rollout of AI Solutions | 641 | GlobeNewswire (Europe) | PETACH TIKVA, Israel, Nov. 19, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical imaging technology company, today announced that the parties... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ASTRAZENECA | 163,45 | +0,37 % | AstraZeneca erhält EU-Zulassungsempfehlung für Bluthochdruckmittel Baxfendy | DJ AstraZeneca erhält EU-Zulassungsempfehlung für Bluthochdruckmittel Baxfendy
Von Adria Calatayud
DOW JONES--Astrazeneca hat von der Europäischen Arzneimittel-Agentur für das Medikament Baxfendy... ► Artikel lesen | |
| EYEPOINT | 0,244 | -3,17 % | EyePoint auf UBS-Biopharma-Konferenz: DME-Hoffnungen federn Rückschlag bei feuchter AMD ab | ||
| IONIS PHARMACEUTICALS | 25,420 | +1,68 % | Ionis Pharmaceuticals, Inc.: TRYNGOLZA (olezarsen) approved in the EU for severe hypertriglyceridemia (sHTG) | - TRYNGOLZA is now the first and only RNA-targeted therapy indicated in the EU for sHTG =880 mg/dL (=10 mmol/L) - - Approximately 700,000 people in the EU5 are estimated to have triglyceride... ► Artikel lesen | |
| CSPC PHARMA | 0,901 | 0,00 % | CSPC Pharmaceutical Group Ltd. Announces Rise In Nine Months Bottom Line | ||
| SELLAS LIFE SCIENCES | 16,650 | +1,83 % | Aktie verdreifacht sich: Sellas Life Sciences: Neuer Krebsimpfstoff beflügelt | © Foto: adobe.stock.comDie Aktie von Sellas Life Sciences verzeichnet nach überzeugenden Studiendaten zu einem experimentellen Blutkrebs-Impfstoff einen historischen Kurssprung Enthaltene Werte: US81642T2096Den... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 364,20 | +0,41 % | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | ||
| ACADIA PHARMACEUTICALS | 16,555 | +1,88 % | Oppenheimer senkt Kursziel für Acadia Pharmaceuticals wegen Pipeline-Aussichten | ||
| CATALYST PHARMACEUTICALS | 27,300 | +2,63 % | Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals | The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare DiseasesCompletion of the transaction gives Angelini Pharma ownership... ► Artikel lesen | |
| OPUS GENETICS | 3,620 | +1,12 % | Opus Genetics, Inc.: Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027 | OPGx-BEST1 demonstrated a favorable safety and tolerability profile with no serious adverse events or dose-limiting toxicities observed All five participants demonstrated clinically meaningful improvement... ► Artikel lesen | |
| CHUGAI PHARMACEUTICAL | 41,090 | -0,44 % | Chugai Pharma Q3 Earnings Rise On Sales Growth; FY26 Outlook Unchanged | TOKYO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. (CHGCF.PK), reported revenue of JPY 1,068.1 billion for the nine months ended September 30, 2026, marking a 17.2% increase from the previous... ► Artikel lesen | |
| SAVARA | 4,353 | +0,90 % | H.C. Wainwright initiates Savara stock coverage with buy rating | ||
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2027 ended September 30, 2026 and Provides Conference Call Information | Conference Call Scheduled for Friday, November 13, 2026 at 11:30 AM ESTNorthvale, New Jersey--(Newsfile Corp. - November 12, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company")... ► Artikel lesen | |
| GALECTIN THERAPEUTICS | 2,580 | +4,88 % | Galectin Therapeutics GAAP EPS of -$0.04 beats by $0.01 | ||
| BIODEXA PHARMACEUTICALS | 1,350 | -7,53 % | XFRA NEW INSTRUMENTS AVAILABLE ON 28.10.2026 | The following instruments on XETRA do have their first trading 28.10.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 28.10.2026
Aktien
1 US59564R8640 Biodexa Pharmaceuticals... ► Artikel lesen | |
| NEURIZON THERAPEUTICS | 0,026 | 0,00 % | NEURIZON THERAPEUTICS LIMITED: Bell Potter Healthcare Conference Presentation |